Langley Richard G, Cherman Andréa M, Gupta Aditya K
Dalhousie University, Center for Clinical Research, 5820 University Avenue, Halifax, NS, B3H 1V7, Canada.
Expert Opin Pharmacother. 2005 Oct;6(13):2327-33. doi: 10.1517/14656566.6.13.2327.
Psoriasis is a chronic, inflammatory skin disease. Historically, phototherapy or immunosuppressive agents have been the first line of treatment for patients with severe psoriasis; however, the long-term use of these agents is limited by dose-dependent toxicities. Alefacept was the first biological agent approved in both the US and Canada for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Alefacept is a remittive therapy that selectively reduces memory T cells. The efficacy and safety of up to two courses of alefacept have been demonstrated in clinical trials, and thus, this review focuses on new data to optimise the use of this biological agent. Emerging data indicates that multiple courses of alefacept for the long-term treatment of psoriasis are safe and effective. In addition, data are reviewed on the use of alefacept in combination with other agents and in other diseases, including psoriatic arthritis.
银屑病是一种慢性炎症性皮肤病。从历史上看，光疗或免疫抑制剂一直是重度银屑病患者的一线治疗方法；然而，这些药物的长期使用受到剂量依赖性毒性的限制。阿法赛特是美国和加拿大首个批准用于治疗中重度慢性斑块状银屑病成人患者的生物制剂。阿法赛特是一种缓解性疗法，可选择性减少记忆T细胞。临床试验已证明阿法赛特两个疗程的疗效和安全性，因此，本综述聚焦于优化该生物制剂使用的新数据。新出现的数据表明，阿法赛特多个疗程用于银屑病的长期治疗是安全有效的。此外，还综述了阿法赛特与其他药物联合使用以及在其他疾病（包括银屑病关节炎）中的应用数据。
